• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.14% Nasdaq Down0.35%

    More On ALPMY



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    • Income Statement
    • Balance Sheet
    • Cash Flow

    Astellas Pharma, Inc. (ALPMY)

    -Other OTC
    14.21 Up 0.18(1.28%) 3:57PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Astellas Pharma, Inc.
    2-5-1, Nihonbashi-Honcho
    Tokyo, 103-8411
    Japan - Map
    Phone: 81 3 3244 3000
    Website: http://www.astellas.com

    Index Membership:N/A
    Full Time Employees:17,113

    Business Summary 

    Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., Dana-Farber Cancer Institute, and Ventana Medical Systems, Inc. The company was founded in 1923 and is headquartered in Tokyo, Japan.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Astellas Pharma, Inc.

    Key Executives 
    Mr. Yoshihiko Hatanaka ,
    Chief Exec. Officer, Pres and Representative Director
    Mr. Yoshirou Miyokawa ,
    Chief Admin. Officer, Chief Compliance Officer, Exec. VP, Representative Director, Chairman of Global Compliance Committee and Member of Compensation Committee
    Mr. Mitsunori Matsuda ,
    Pres of Technology, Sr. Corp. Exec. and Sr. VP
    Mr. Jeffrey A. Winton , 57
    Chief Communications Officer and Sr. VP
    Mr. Yukihiko Sato ,
    Pres of Sales & Marleting, Sr. Corp. Exec. and Sr. VP
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.